2552.HK - Hua Medicine (Shanghai) Ltd.

HKSE - HKSE Delayed Price. Currency in HKD
6.900
0.000 (0.00%)
As of 3:42PM HKT. Market open.
Stock chart is not supported by your current browser
Previous Close6.900
Open7.000
Bid6.870 x 0
Ask7.000 x 0
Day's Range6.800 - 7.000
52 Week Range6.000 - 8.920
Volume4,500
Avg. Volume58,438
Market Cap6.541B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Volatility 101: Should Hua Medicine (Shanghai) (HKG:2552) Shares Have Dropped 11%?
    Simply Wall St.

    Volatility 101: Should Hua Medicine (Shanghai) (HKG:2552) Shares Have Dropped 11%?

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...

  • Hua Medicine (Shanghai) Ltd. (HKG:2552): The Best Of Both Worlds
    Simply Wall St.

    Hua Medicine (Shanghai) Ltd. (HKG:2552): The Best Of Both Worlds

    I've been keeping an eye on Hua Medicine (Shanghai) Ltd. (HKG:2552) because I'm attracted to its fundamentals. Looking...

  • GlobeNewswire

    Hua Medicine – Business & Pipeline Update

    TrialProductsExploratoryNDA EnablingDescription / Indication HMM0301Dorzagliatin (HMS5552) Phase III ongoingDrug-naïve T2D HMM0302Dorzagliatin + Metformin Phase III.

  • GlobeNewswire

    Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the United States

    Hua Medicine (2552.HK), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today dosing of the first patient in a Phase I drug-drug interaction trial of HMS5552 (dorzagliatin) in patients with insufficiently controlled T2D with metformin, DPP-4 inhibitor, or SGLT2 inhibitor, alone or in combination therapy (metformin plus DPP-4 inhibitor, or metformin plus SGLT-2 inhibitor). The trial is a pharmacokinetic and pharmacodynamic study of dorzagliatin in combination with empagliflozin to investigate the PK/PD of each drug alone or in combination. The primary endpoints are pharmacokinetic interaction between dorzagliatin and empagliflozin, and safety and tolerability of dorzagliatin with simultaneous administration of empagliflozin.

  • GlobeNewswire

    Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliatin

    Hua Medicine (2552.HK), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today the completion of patient enrollment for a Phase III monotherapy trial of HMS5552 (dorzagliatin).  Hua Medicine therefore expects to release the topline results in 4th quarter of 2019. “I am very proud to announce this milestone,” said Dr. Li Chen, Chief Executive Officer of Hua Medicine. “With 120 million Type 2 diabetics in China, this gets us one step closer to bringing dorzagliatin, a novel, first-in-class drug to the Chinese market.

  • GlobeNewswire

    Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor in the United States

    Stock Code: 2552.HK) a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes (T2D), announced today dosing of the first patient in a clinical trial of HMS5552 (dorzagliatin) in patients with insufficiently controlled blood glucose levels with metformin, DPP-4 inhibitor, or SGLT-2 inhibitor, alone or in combination therapy. The trial is a pharmacokinetic (PK) and pharmacodynamic (PD) study of dorzagliatin in combination with sitagliptin to investigate the PK/PD of each drug alone or in combination. The primary endpoints are pharmacokinetic and pharmacodynamic interaction between dorzagliatin and sitagliptin, and safety and tolerability of dorzagliatin with simultaneous administration of sitagliptin.

  • Reuters

    China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

    Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday. The firm aims to take advantage of rules introduced by Hong Kong's stock exchange in April allowing listings from pre-revenue biotechs, as the bourse competes to attract startups. Junshi Biosciences priced shares at HK$19.38 ($2.48) each, the people said, having indicated a price of up to HK$20.38.

  • Investing.com

    China’s Innovent Extends Gain from Solid HK IPO

    Investing.com - The shares of China’s Innovent Biologics Inc (HK:1801) continued to rise on Friday morning in Asia, two days after their initial public offering.